Wellington Blood and Cancer Centre, Capital and Coast District Health Board, Wellington, New Zealand.
Intern Med J. 2013 Oct;43(10):1151-4. doi: 10.1111/imj.12226.
Australian guidelines for neutropenic fever recommend piperacillin/tazobactam (PIP-TAZ) or cefepime for first-line empiric treatment of neutropenic fever. We compared outcomes among haematology patients before and after changing our first-line neutropenic fever treatment from imipenem to PIP-TAZ. Forty-five patients received imipenem and 60 PIP-TAZ. Despite a higher rate of antibiotic modification in the PIP-TAZ cohort, treatment success and time to defervescence were similar, with a trend towards fewer Clostridium difficile infections in the PIP-TAZ cohort.
澳大利亚中性粒细胞减少性发热指南建议哌拉西林/他唑巴坦（PIP-TAZ）或头孢吡肟作为中性粒细胞减少性发热经验性一线治疗药物。我们比较了血液病患者在将一线中性粒细胞减少性发热治疗药物从亚胺培南改为 PIP-TAZ 前后的结果。45 例患者接受了亚胺培南治疗，60 例患者接受了 PIP-TAZ 治疗。尽管 PIP-TAZ 组抗生素调整率较高，但治疗成功率和退热时间相似，PIP-TAZ 组艰难梭菌感染率呈下降趋势。
